AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2036070 — intervention group
Group type: COMPARATOR
Intervention: Madopar M (standard preparation)
Number of subjects: 9
Study 7225476 — intervention group
Group type: EXPERIMENTAL
Intervention: Fronto-frontal ECT
Number of subjects: 2
Study 7225476 — intervention group
Group type: COMPARATOR
Intervention: Temporo-parietal ECT
Number of subjects: 2
Study 31087825 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 237
Study 31087825 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA (STMN1 and PPP1R9B)
Number of subjects: 237
Study 31087825 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA (miR‐3688 and miR‐5695)
Number of subjects: 237
Study 31087825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (baseline depression severity, STMN1, and miR‐5695)
Number of subjects: 237
Study 31087825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 27515070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (Arm 1: immediate cessation of methotrexate; Arm 2: 4 weeks' overlap with decreasing methotrexate dose)
Number of subjects: 489
Study 27515070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 489
Study 25856211 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole or clomiphene citrate (up to five cycles)
Number of subjects: 710
Study 25856211 — intervention group
Group type: COMPARATOR
Intervention: Both partners smoked
Number of subjects: 710
Study 25856211 — intervention group
Group type: EXPERIMENTAL
Intervention: At least three sexual intercourse attempts over the previous 4 weeks
Number of subjects: 710
Study 24916903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipocalin-2 treatment in microglia
Number of subjects: 0
Study 24916903 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipocalin-2 treatment in astrocytes
Number of subjects: 0
Study 24916903 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from lipocalin-2-treated astrocytes
Number of subjects: 0
Study 24916903 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media from lipocalin-2-treated microglia
Number of subjects: 0
Study 24916903 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal expression of lipocalin-2
Number of subjects: 0
Study 22541682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase push protocol (30 minutes)
Number of subjects: 82
Study 22541682 — intervention group
Group type: COMPARATOR
Intervention: Alteplase dwell protocol (30 minutes with additional 90 minutes if necessary)
Number of subjects: 82
Study 22541682 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase push protocol
Number of subjects: 82
Study 22541682 — intervention group
Group type: COMPARATOR
Intervention: Alteplase dwell protocol
Number of subjects: 82
Study 20215128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin for 5 days plus doxycycline for 8 weeks
Number of subjects: 82
Study 20215128 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin for 2 weeks plus doxycycline for 45 days
Number of subjects: 82
Study 18409186 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicious Digital Rectal Examination (DRE)
Number of subjects: 7280
Study 18409186 — intervention group
Group type: EXPERIMENTAL
Intervention: Examiner variability in DRE interpretation
Number of subjects: 7280
Study 15839376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mention of organ scarcity and wait list demand statistics (n=66)
Number of subjects: 143
Study 15839376 — intervention group
Group type: COMPARATOR
Intervention: No mention of organ scarcity and wait list demand statistics (n=77)
Number of subjects: 143
Study 12219864 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem (HSE) participants
Number of subjects: 0
Study 12219864 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem (LSE) participants
Number of subjects: 0
Study 10617237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) at doses of 0-5 microg/kg/min
Number of subjects: 20
Study 10617237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD)
Number of subjects: 20
Study 8830834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12
Study 8830834 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 12
Study 1425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 286
Study 1425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (bromocriptine + levodopa) for 5 years
Number of subjects: 286
Study 1425818 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone therapy for 5 years
Number of subjects: 286
Study 1425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine alone followed by levodopa
Number of subjects: 286
Study 1425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained combination therapy for 5 years
Number of subjects: 286
Study 1425818 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa alone followed by bromocriptine
Number of subjects: 286
Study 4065703 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous morphine infusion
Number of subjects: 42
Study 4065703 — intervention group
Group type: COMPARATOR
Intervention: Scheduled intramuscular morphine injections
Number of subjects: 42
Study 30854694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 117
Study 30854694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 117
Study 30854694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 29128486 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sufentanil (bolus 0.25 µg/kg)
Number of subjects: 60
Study 29128486 — intervention group
Group type: COMPARATOR
Intervention: Standard dose sufentanil (bolus 0.5 µg/kg)
Number of subjects: 60
Study 25496243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and immediate temporary restoration
Number of subjects: 48
Study 25496243 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement and early restoration
Number of subjects: 48
Study 25496243 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implant placement and immediate temporary restoration
Number of subjects: 48
Study 25496243 — intervention group
Group type: EXPERIMENTAL
Intervention: Early implant placement and early restoration
Number of subjects: 48
Study 24637202 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 122
Study 24637202 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 122
Study 22464936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature walk
Number of subjects: 20
Study 20166789 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention motivation and behavioral self-efficacy
Number of subjects: 732
Study 20166789 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer and venue supports
Number of subjects: 732
Study 16683122 — intervention group
Group type: EXPERIMENTAL
Intervention: CAOS (electromagnetic image guided surgery, NAVITRAK)
Number of subjects: 12
Study 16683122 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 12
Study 16683122 — intervention group
Group type: EXPERIMENTAL
Intervention: CAOS
Number of subjects: 12
Study 16683122 — intervention group
Group type: COMPARATOR
Intervention: CT compared to dissection
Number of subjects: 12
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 positive cases in DLBCL (n=32)
Number of subjects: 126
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 positive cases in T-LBL (n=8)
Number of subjects: 126
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 positive cases in follicular lymphoma (n=14)
Number of subjects: 126
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 positive cases in T/NK cell lymphoma (n=6)
Number of subjects: 126
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63 overexpression (above 30%) in DLBCL
Number of subjects: 126
Study 16224147 — intervention group
Group type: EXPERIMENTAL
Intervention: p63+/p53+ cases
Number of subjects: 126
Study 12362542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 1300
Study 12362542 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily injection of low molecular weight heparin
Number of subjects: 1300
Study 12362542 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for longer-term secondary prophylaxis
Number of subjects: 1300
Study 12362542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical probability assessment and D-dimer measurement
Number of subjects: 1300
Study 12362542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic examination of the leg and CT scan of pulmonary vessels
Number of subjects: 1300
Study 10211851 — intervention group
Group type: EXPERIMENTAL
Intervention: High force resistance exercise protocol
Number of subjects: 10
Study 10211851 — intervention group
Group type: EXPERIMENTAL
Intervention: High power resistance exercise protocol
Number of subjects: 10
Study 8575688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pure follicle-stimulating hormone (pFSH) (Metrodin)
Number of subjects: 0
Study 8575688 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 0
Study 2406327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose allergoid (maximal dose: 2000 PNU)
Number of subjects: 57
Study 2406327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose allergoid (maximal dose: 10,000 PNU)
Number of subjects: 57
Study 2406327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6107548 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside-charcoal
Number of subjects: 46
Study 6107548 — intervention group
Group type: COMPARATOR
Intervention: charcoal alone
Number of subjects: 46
Study 6107548 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 46
Study 30883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 135
Study 30883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 5.25 mg/kg
Number of subjects: 135
Study 30883839 — intervention group
Group type: COMPARATOR
Intervention: Cladribine tablets 3.5 mg/kg and 5.25 mg/kg
Number of subjects: 135
Study 28333513 — intervention group
Group type: EXPERIMENTAL
Intervention: Client feedback in group psychotherapy
Number of subjects: 159
Study 28333513 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 159
Study 26102724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/Hydrochlorothiazide 12.5 mg (NH)
Number of subjects: 124
Study 26102724 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg/Hydrochlorothiazide 12.5 mg (IH)
Number of subjects: 124
Study 23916740 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafin BDP/F 400/24 μg
Number of subjects: 3
Study 23916740 — intervention group
Group type: COMPARATOR
Intervention: High dose FP/S 1000/100 μg
Number of subjects: 3
Study 23916740 — intervention group
Group type: COMPARATOR
Intervention: Medium dose FP/S 500/100 μg
Number of subjects: 3
Study 21995901 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD BIV pacing
Number of subjects: 18
Study 21995901 — intervention group
Group type: COMPARATOR
Intervention: DDD RV pacing
Number of subjects: 18
Study 19297655 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed methodology for estimating parameters of conditional means and variances of gap times
Number of subjects: 0
Study 19297655 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial of asthma prevention
Number of subjects: 0
Study 16763490 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-containing highly active antiretroviral therapy (zidovudine + lamivudine + efavirenz)
Number of subjects: 740
Study 16763490 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-containing highly active antiretroviral therapy
Number of subjects: 740
Study 16763490 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 740
Study 15158606 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of porins (S. typhi outer‐membrane proteins)
Number of subjects: 0
Study 11275392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsterdam Pain Management Index
Number of subjects: 313
Study 11275392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Education Program
Number of subjects: 313
Study 11275392 — intervention group
Group type: COMPARATOR
Intervention: Pain Intensity Markers
Number of subjects: 313
Study 11275392 — intervention group
Group type: COMPARATOR
Intervention: Pain Relief Scale
Number of subjects: 313
Study 11275392 — intervention group
Group type: COMPARATOR
Intervention: Patient Satisfaction Scale
Number of subjects: 313
Study 11275392 — intervention group
Group type: COMPARATOR
Intervention: Pain Management Indexes
Number of subjects: 313
Study 9786640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdentures (mainly implant-borne on a transmandibular implant)
Number of subjects: 68
Study 9786640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosa-borne overdentures on two cylindric permucosal IMZ implants
Number of subjects: 68
Study 9786640 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures in the mandible
Number of subjects: 68
Study 9786640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainly implant-borne (TMI) and mucosa-implant-borne (IMZ) implant systems
Number of subjects: 68
Study 7888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (120 mg/week, administered biweekly)
Number of subjects: 107
Study 7888419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 7888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 107
Study 3075383 — intervention group
Group type: EXPERIMENTAL
Intervention: IRS 19 (polyvalent bacterial lysate)
Number of subjects: 80
Study 3075383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31361655 — intervention group
Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 1048
Study 31361655 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1048
Study 28856601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening)
Number of subjects: 70
Study 28856601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27004289 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-collar-treated implants
Number of subjects: 36
Study 27004289 — intervention group
Group type: COMPARATOR
Intervention: Nanosurface-treated implants
Number of subjects: 36
Study 25710379 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11
Study 25710379 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 normal-weight men)
Number of subjects: 11
Study 22045827 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 0.5%
Number of subjects: 285
Study 22045827 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 1%
Number of subjects: 285
Study 22045827 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol 3%
Number of subjects: 285
Study 22045827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 20684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin extensibility measured by suction cup (SC)
Number of subjects: 31
Study 20684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin consistency measured by soft tissue stiffness meter (STSM)
Number of subjects: 31
Study 20684735 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tests for skin extensibility
Number of subjects: 31
Study 20684735 — intervention group
Group type: COMPARATOR
Intervention: Normal skin extensibility
Number of subjects: 31
Study 18487901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 20
Study 18487901 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 20
Study 15986744 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct neuro-muscular neurotization associated with muscular transfer (latissimus dorsi, triceps, pectoralis major)
Number of subjects: 54
Study 15986744 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi transfer
Number of subjects: 54
Study 15986744 — intervention group
Group type: EXPERIMENTAL
Intervention: Triceps transfer
Number of subjects: 54
Study 15986744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis major transfer
Number of subjects: 54
Study 12560428 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic adjuvant chemotherapy (in all treatment arms)
Number of subjects: 1174
Study 10472226 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with hyperbaric lidocaine 50 mg ml‐1 (85‐100 mg)
Number of subjects: 60
Study 10472226 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with neuromuscular block
Number of subjects: 60
Study 7593777 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 12 weeks)
Number of subjects: 111
Study 7593777 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 12 weeks) after initial treatment
Number of subjects: 111
Study 7593777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 1948277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 500 mg fortnightly
Number of subjects: 334
Study 1948277 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 300 mg base weekly plus Fansidar (1000 mg sulfadoxine and 50 mg pyrimethamine) fortnightly
Number of subjects: 334
Study 1948277 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 300 mg base weekly
Number of subjects: 334
Study 348251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for six weeks
Number of subjects: 24
Study 348251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 348251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g daily for six weeks (subsequent treatment for non-healing controls)
Number of subjects: 24
Study 348251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 24
Study 31512160 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CP) applied twice a day for 4 days post-surgery
Number of subjects: 148
Study 31512160 — intervention group
Group type: COMPARATOR
Intervention: Control group (only mobilization)
Number of subjects: 148
Study 31288944 — intervention group
Group type: EXPERIMENTAL
Intervention: Magseed
Number of subjects: 200
Study 31288944 — intervention group
Group type: COMPARATOR
Intervention: WGL
Number of subjects: 200
Study 28877822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg)
Number of subjects: 122
Study 28877822 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 122
Study 26255508 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of relaxing needling technique combined with wheat-grain moxibustion
Number of subjects: 90
Study 26255508 — intervention group
Group type: COMPARATOR
Intervention: Simple relaxing needling
Number of subjects: 90
Study 26255508 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 90
Study 23674290 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical decisions with available level I evidence (Group 1)
Number of subjects: 393
Study 23674290 — intervention group
Group type: COMPARATOR
Intervention: Medical decisions without available level I evidence (Group 2)
Number of subjects: 393
Study 22022503 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimpanzee conservation commercial
Number of subjects: 165
Study 22022503 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercials containing 'entertainment' chimpanzees
Number of subjects: 165
Study 22022503 — intervention group
Group type: COMPARATOR
Intervention: Control footage of the natural behavior of wild chimpanzees
Number of subjects: 165
Study 22022503 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunity to donate to a conservation charity after viewing
Number of subjects: 165
Study 19623189 — intervention group
Group type: EXPERIMENTAL
Intervention: HEALTHY intervention (FLASH modules)
Number of subjects: 6
Study 19623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Family outreach strategy
Number of subjects: 6
Study 19623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Total school food and physical education environmental changes
Number of subjects: 6
Study 16822626 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus MT 2.5mg/day for 4 months (GII)
Number of subjects: 85
Study 16822626 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus MT 2.5mg/day for 2 months, then HRT plus placebo for 2 months (GIV)
Number of subjects: 85
Study 16822626 — intervention group
Group type: COMPARATOR
Intervention: HRT plus placebo for 4 months (GI)
Number of subjects: 85
Study 16822626 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus placebo for 2 months, then HRT plus MT 2.5mg/day for 2 months (GIII)
Number of subjects: 85
Study 15298339 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (low in saturated fat, high in fibre, low glycaemic index, rich in complex carbohydrates)
Number of subjects: 20
Study 15298339 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate cycling exercise (30 min, three times per week)
Number of subjects: 20
Study 15298339 — intervention group
Group type: COMPARATOR
Intervention: Control period (8 weeks before randomization)
Number of subjects: 20
Study 11204933 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 36
Study 11204933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg)
Number of subjects: 36
Study 11204933 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 36
Study 11204933 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) and Lacidipine (4 mg) in hypertensive patients
Number of subjects: 36
Study 9449682 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (50 pmol/kg.h)
Number of subjects: 20